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Abstract
Background: High-resolution 3D imaging of intact tissue facilitates cellular and subcellular analyses of complex
structures within their native environment. However, difficulties associated with immunolabelling and imaging
fluorescent proteins deep within whole organs have restricted their applications to thin sections or processed tissue
preparations, precluding comprehensive and rapid 3D visualisation. Several tissue clearing methods have been
established to circumvent issues associated with depth of imaging in opaque specimens. The application of these
techniques to study the elaborate architecture of the mouse mammary gland has yet to be investigated.
Methods: Multiple tissue clearing methods were applied to intact virgin and lactating mammary glands, namely 3D
imaging of solvent-cleared organs, see deep brain (seeDB), clear unobstructed brain imaging cocktails (CUBIC) and
passive clarity technique. Using confocal, two-photon and light sheet microscopy, their compatibility with whole-
mount immunofluorescent labelling and 3D imaging of mammary tissue was examined. In addition, their suitability
for the analysis of mouse mammary tumours was also assessed.
Results: Varying degrees of optical transparency, tissue preservation and fluorescent signal conservation were
observed between the different clearing methods. SeeDB and CUBIC protocols were considered superior for volumetric
fluorescence imaging and whole-mount histochemical staining, respectively. Techniques were compatible with 3D
imaging on a variety of platforms, enabling visualisation of mammary ductal and lobulo-alveolar structures at vastly
improved depths in cleared tissue.
Conclusions: The utility of whole-organ tissue clearing protocols was assessed in the mouse mammary gland. Most
methods utilised affordable and widely available reagents, and were compatible with standard confocal microscopy.
These techniques enable high-resolution, 3D imaging and phenotyping of mammary cells and tumours in situ, and will
significantly enhance our understanding of both normal and pathological mammary gland development.
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Background
The mammary gland is composed of a branching epithe-
lial ductal network deeply embedded within a vascu-
larised stromal matrix made up of adipocytes, fibroblasts
and immune cells [1]. Due to its capacity for rapid
growth and regeneration, the mouse mammary gland is
a powerful model in which to study a range of develop-
mental processes associated with tissue morphogenesis
and remodelling, and provides important insights into
the perturbations that give rise to breast cancer [1].
However, visualisation of the complex cellular networks
within the intact mammary epithelium is greatly im-
peded by the lipid-rich and optically opaque nature of
this organ. As a result, immunolabelling and fluores-
cence imaging of mammary tissue has traditionally been
performed using thin tissue sections with assumptions
about the architectural context and uniformity of a par-
ticular 2D plane. Whilst 3D imaging has recently been
used to investigate mammary stem cell dynamics [2–4]
and binucleated cells in lactational alveoli [5], these
studies have relied on tissue microdissection [2, 5]
or enzymatic digestion [3]. Consequently, visualisation of
the mammary epithelial tree at single-cell resolution
within its native stroma remains a fundamental challenge
in mammary gland research.
The utility of rendering tissue optically transparent has
been appreciated for over a century [6]. However, recent
advances in fluorescence microscopy have heralded the
development of numerous whole-organ tissue clearing
methods aimed at improving optical access and depth of
imaging in intact specimens (reviewed in [7]). These
methods are primarily based on mitigating light scatter-
ing caused by heterogeneous cellular components with
different refractive indices (RIs). Techniques broadly rely
either on organic solvent-based or hydrophilic reagent-
based clearing solutions to homogenise RIs within tis-
sue, and may also include prior hydrogel embedding
to stabilise cellular structures. Whilst many protocols
were originally optimised for the central nervous sys-
tem and whole embryos, recent refinements in tissue
clearing techniques have facilitated exceptional optical
access to many other mammalian tissues. However,
the application of these techniques to the mammary
gland is yet to be explored.
Here, we describe the application of four leading tissue
clearing protocols, namely three-dimensional imaging
of solvent-cleared organs (3DISCO) [8], see deep brain
(SeeDB) [9], clear unobstructed brain imaging cocktails
(CUBIC) [10] and passive clarity technique (PACT) [11],
to virgin and lactating mammary glands. Whilst the
underlying principles for achieving tissue transparency
are fundamentally different in each of these methods,
the majority utilise simple and affordable reagents, and
can be completed within two weeks.
3DISCO [8] is based on earlier clearing methods that
use high-index organic solvents such as benzyl alcohol
benzyl benzoate (BABB) [12, 13], and can be combined
with optimised whole-mount immunolabelling proce-
dures (termed iDISCO) [14]. To date, 3DISCO remains
the only method previously applied to mammary tissue,
albeit superficially [8]. PACT [11] relies on hydrogel em-
bedding to stabilise cellular structures prior to tissue
delipidation using ionic detergents. Due to the need for
custom electrophoresis equipment, CLARITY [15] is diffi-
cult to implement and can lead to heat-induced tissue
damage and epitope loss [11]. The PACT protocol cir-
cumvents these issues, relying instead on passive diffusion.
Furthermore, PACT utilises more economical RI match-
ing solutions (RIMS and sRIMS), an additional benefit
over CLARITY. CUBIC [10] is a urea-based clearing re-
agent that includes aminoalcohols and detergents to re-
move lipids and homogenise RIs within tissue. In addition,
CUBIC reagents decolourise blood by eluting the heme
chromophore, further enhancing optical transparency by
minimising light absorption [16]. Finally, SeeDB [9] is a
water-based optical clearing agent that utilises saturated
solutions of fructose and alpha-thioglycerol (which limits
autofluorescence) for RI matching.
We compared these four protocols for optical transpar-
ency and tissue preservation in the intact mammary gland,
in addition to their compatibility with immunofluorescent
labelling and 3D imaging of mammary epithelial cells.
Their suitability for the analysis of mammary tumours was
also investigated. Using standard confocal and advanced
imaging techniques, ductal and lobulo-alveolar structures
could be readily visualised in cleared tissue, with varying
degrees of fluorescent signal preservation between the dif-
ferent methods. Overall, our results placed SeeDB and
CUBIC as methods of choice for high-resolution fluores-
cence imaging and whole-mount histochemical staining of
mammary glands. The ability to visualise the mammary
epithelial tree at single cell resolution within its native
stroma will provide invaluable insight into mammary
gland development and tumourigenesis.
Methods
Reagents and antibodies
The following reagents were purchased from Sigma
Aldrich: neutral buffered formalin (NBF), dimethyl
sulfoxide (DMSO), tetrahydrofuran (THF), dichloro-
methane (DCM), dibenzyl ether (DBE), benzyl alcohol,
benzyl benzoate, urea, N,N,N’,N’-tetrakis(2-hydroxy-
propyl)ethylenediamine, 2,2′,2″-nitrilotriethanol, fruc-
tose, α-thioglycerol, D-sorbitol and 4′,6-diamidino-2-
phenylindole (DAPI) dilactate. RapiClear-CLARITY
Specific (RC-CS) Solution and Mounting Medium and
iSpacer imaging chambers were purchased from the
SunJin Lab: 2,2′-Azobis[2-(2-imidazolin-2-yl)propane]
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dihydrochloride was purchased from Wako Pure Chem-
ical Industries. Imaging dishes were purchased from Ibidi
(81158). Acrylamide (40%) was purchased from Bio-Rad
Laboratories. Sodium dodecyl sulphate (SDS) was
purchased from Melford Laboratories. Triton-X100 was
purchased from VWR International. The following pri-
mary antibodies were used for immunostaining: rabbit
anti-α-smooth muscle actin (SMA) (Abcam, ab5694;
1:200-1:300 for 2D and 3D studies), rabbit anti-keratin 5
(BioLegend, 905501; 1:100 (3D)), rat anti-cytokeratin 8
(Developmental Studies Hybridoma Bank, TROMA-I;
1:50 (3D) or 1:150-200 (2D)), rabbit anti-E-cadherin
(Cell Signaling, 3195; 1:50 (3D) or 1:200 (2D)), mouse
anti-E-cadherin (BD Transduction Laboratories,
610182; 1:300 (2D)), rabbit anti-cleaved caspase 3 (Cell
Signaling, 9661S; 1:200 (2D)) and rabbit anti-human epi-
dermal growth factor receptor 2 (HER2) (DAKO, A0485;
1:300 (3D) or 1:500 (2D)). The following Alexa Fluor con-
jugated secondary antibodies were purchased from Life
Technologies and diluted 1:500 (2D and 3D studies) in
blocking buffer: goat anti-rat Cy3 (A10522), goat anti-
rabbit 647 (A21245) and chicken anti-rabbit 647
(A21443). Anti-rabbit horseradish peroxidase (HRP)-con-
jugated secondary antibody was purchased from DAKO
(P0448; 1:500).
Mice
Mice (C57BL/6 and BALB/c) were housed in indi-
vidually ventilated cages under a 12:12 h light-dark
cycle, with water and food available ad libitum. Mice
were euthanized by dislocation of the neck or ter-
minal anaesthesia. All tissue from virgin mice was
harvested during puberty (5–8 weeks). For studies
during lactation, mice were mated with studs, allowed
to litter and tissue was harvested between lactation days
2 to 10. Mammary glands (excluding the cervical (first)
pair) were excised and immediately spread and fixed on
card (Tetra Pak) in 10% NBF for 9 h at room temperature,
unless otherwise specified. A 9-h fix provided optimal
staining for all antibodies used in this study; however,
SMA and K8 also performed well with overnight fixation
(4 °C). Fixed tissue was stored at 4 °C in phosphate-
buffered saline (PBS) containing sodium azide (0.05% (w/
v)) for up to 8 weeks.
Syngeneic mammary tumours were established by
orthotopically implanting 5 × 103 TUBO cells [17], into
the abdominal (fourth) mammary gland. This cloned cell
line was established from a mammary carcinoma that
spontaneously arose in a BALB-neuT mouse and there-
fore carries the Her-2/neu oncogene driven by the
MMTV promoter. Mice were monitored regularly and
tumours were harvested before exceeding humane end-
points (approx. 4–5 weeks).
3DISCO-based clearing and immunohistochemical
analysis (IHC)
3DISCO was performed as previously described [8].
Solvent immersion times were adjusted for mammary
tissue pieces (approx. 10 × 10 × 1 mm) as follows: 50%
(v/v) THF in H2O (40 min), 70% (v/v) THF in H2O
(40 minutes), 80% (v/v) THF in H2O (40 minutes),
100% (v/v) THF (3 × 40 minutes), and DCM (15 mi-
nutes). All solvent immersion steps were performed
in glass vials. Although DBE is reported to be a su-
perior optical clearing agent vs. BABB [8], this solvent
requires specialised imaging chambers and solvent-
resistant adhesive (e.g. dental cement), and can se-
verely damage objectives if the chamber fails. Thus,
we used BABB as the final clearing agent for trans-
mission and confocal imaging in this study. BABB
was prepared as a mixture of benzyl alcohol and ben-
zyl benzoate (1:2). Immunostaining was performed as
per the iDISCO protocol [14], with a methanol pre-
treatment. Following the iDISCO immunolabelling
protocol, samples were washed in PBS and incubated
with DAPI (10 μM) for 2–3 h, cleared using the
3DISCO protocol and imaged the same day.
PACT-based clearing and IHC
The A4P0 hydrogel formulation was selected for PACT-
based clearing of the mouse mammary gland [11]. A4P0
was prepared to contain acrylamide (4% (v/v)), 2,2′-Azo-
bis[2-(2-imidazolin-2-yl)propane] dihydrochloride (0.25%
(w/v)) in PBS. PACT-clearing solution consisted of SDS
(8% (w/v)) in distilled water, pH 7.5. Mammary tissue
pieces (approx. 10 × 10 × 1 mm) were incubated in A4P0
hydrogel monomer for 4 days at 4 °C and heated to 37 °C
in a water bath for 4–6 h. Excess gel was carefully re-
moved from the tissue and samples were immersed in
PACT clearing solution for 24 h at room temperature.
Samples were immersed in fresh clearing solution, incu-
bated at 37 °C for 4 days (with replenishment every sec-
ond day), and finally washed with PBS containing triton-
X100 (0.1% (w/v)) for 24 h. For immunostaining, samples
were blocked in PBS containing triton-X100 (0.5% (w/v))
with goat serum (10% (v/v)) overnight at 4 °C. Primary
antibodies were diluted in blocking buffer at 4 °C for 4 days
with agitation, tissue was washed (3 × 1 h) in PBS and in-
cubated with Alexa Fluor conjugated secondary antibodies
for 2 days. Samples were washed in PBS and incubated
with DAPI (10 μM) for 2–3 h. PACT-sRIMS samples were
incubated in sRIMS for 4 days or until imaging. sRIMS
was prepared by combining sorbitol (70% (w/v)) in 0.02 M
phosphate buffer [11, 18]. PACT-RC samples were incu-
bated in Rapiclear CS for 4 h and mounted between two
coverslips using RC-CS Mounting Medium and iSpacers
for image acquisition and long-term storage.
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CUBIC-based clearing and IHC
CUBIC-based tissue clearing was performed as previously
described [10], with minor modifications. CUBIC Reagent
1 was prepared as a mixture of urea (25% (w/w)),
N,N,N’,N’-tetrakis(2-hydroxypropyl)ethylenediamine (25%
(w/w)), triton-X100 (15% (w/w)) in distilled water. CUBIC
Reagent 2 was prepared using sucrose (44% (w/w)), urea
(22% (w/w)), 2,2′,2″-nitrilotriethanol (9% (w/w)), triton-
X100 (0.1% (w/w)) in distilled water. CUBIC Reagent 1A
was prepared using urea (10% (w/w))), N,N,N’,N’-tetra-
kis(2-hydroxypropyl)ethylenediamine (5% (w/w)), triton-
X100 (10% (w/w)) and NaCl (25 mM) in distilled water
(unpublished, protocol available at http://cubic.riken.jp/).
Tissue pieces (approx. 10 × 10 × 1 mm) were immersed in
CUBIC Reagent 1 or 1A at 37 °C for 2–3 days, depending
on the size of the tissue piece. For immunostaining
samples were washed and subsequently blocked in PBS
containing triton-X100 (0.5% (w/v)) and goat serum (10%
(v/v)) overnight at 4 °C. Primary antibodies were diluted in
blocking buffer at 4 °C for 4 days with gentle rocking.
Tissue was washed (3 × 1 h) and incubated with Alexa
Fluor conjugated secondary antibodies for 2 days, washed
in PBS and incubated with DAPI (10 μM) for 2–3 h. Sam-
ples were transferred to CUBIC Reagent 2 at 37 °C for at
least 1 day for refractive index matching. Samples were
immersed in CUBIC Reagent 2 for imaging and were im-
aged within 1 week. Diffuse, non-specific fluorescence was
observed using the CUBIC protocol in the absence of the
primary antibodies (Additional file 1: Figure S1, top panel).
Whole-mount histochemical and IHC analysis combined
with CUBIC-based tissue clearing
Excised and fixed mammary glands were immersed in re-
agent 1 for 2–3 days. Glands were removed and stained
with methyl green (0.5% (w/v)), Harris haematoxylin (10%)
or carmine for 1.5–2 h at room temperature with gentle
agitation. After staining, tissues were rinsed twice in tap
water and once in distilled water before de-staining with
acid alcohol (50% ethanol with hydrochloric acid (25 mM))
for 20 minutes and immersion in reagent 2. For detection
of β-glucosidase expression (magenta histochemical stain)
[19], mammary glands were excised and fixed for 4 h at
room temperature. Endogenous β-glucosidase activity was
heat inactivated at 65 °C for 15 minutes in PBS. Whole
mammary glands were incubated for 48 h at 50 °C in a so-
lution containing 1 part Solution A (5-Bromo-6-chloro-3-
indolyl- β-D-glucopyranoside (1% (w/v)) in DMSO) and 25
parts solution B (magnesium chloride (0.02% (w/v)), potas-
sium ferricyanide (0.096% (w/v)) and potassium ferrocyan-
ide (0.13% (w/v)) in PBS). Mammary glands were post-
fixed in 10% NBF overnight at 4 °C and cleared using the
standard CUBIC-clearing protocol.
For whole-mount immunohistochemical analysis, sam-
ples were dehydrated by a methanol series and incubated
overnight in methanol containing DMSO (20%) and
H2O2 (3%) to quench endogenous peroxidase activity
[20]. Samples were rehydrated by methanol series and
blocked and permeabilised in PBS containing BSA (10%
(w/v)) and triton-X100 (1% (w/v)). Samples were incu-
bated with rabbit anti-SMA antibody (1:200) for 4 days
at 4 °C with gentle agitation. After washing, samples
were incubated with anti-rabbit HRP-conjugated second-
ary antibody (1:500) for a further 2 days, before immersion
in reagent 2. Alternatively, quenching, blocking and anti-
body steps can be performed after immersion in reagent 1
with a similar outcome.
SeeDB-based clearing and IHC
SeeDB-based clearing was performed as previously de-
scribed [9], with minor modifications. Briefly, mammary
tissue pieces (approx. 10 × 10 × 1 mm) were blocked and
permeabilised overnight at 4 °C in PBS with triton-X100
(1% (w/v)) and BSA (10% (w/v)). Primary antibodies were
diluted in blocking buffer at 4 °C for 4 days with gentle
rocking. Tissue was washed (3 × 1 h) and incubated with
secondary antibodies for 2 days before further washing
in PBS and incubation with DAPI (10 μM) for 2–3 h.
Samples were serially incubated for 8–16 h (twice daily
changes) in 2–3 mL of 20%, 40%, 60% and 80% (w/v)
fructose in distilled water, and subsequently transferred
to 100% (w/v) fructose solution (24 h) and 115% (w/v)
fructose solution for 24 h or until imaging. All fructose
solutions contained α-thioglycerol (0.5% (v/v)) to in-
hibit the Maillard reaction [9, 21] and incubations were
performed with gentle agitation. For optimal perform-
ance, samples were imaged within 2 weeks of clearing;
however, staining was still observed up to 6 months
after clearing. Diffuse, non-specific fluorescence was
observed using the SeeDB protocol in the absence of
the primary antibodies (Additional file 1: Figure S1,
bottom panel).
Two-dimensional IHC on CUBIC-recovered and SeeDB-
recovered tissue, and formalin-fixed paraffin-embedded
(FFPE) tumour sections
Samples were immersed in PBS for approx. 3 days for
passive rehydration and removal of the clearing agent
[9]. Standard protocols for paraffin processing and em-
bedding using alcohol and xylene were employed.
Paraffin-embedded sections (4–6 μm) were de-waxed in
xylene and antigen retrieval was performed by boiling in
a pressure cooker in tri-sodium citrate buffer (10 mM,
pH 6.0), for 11 minutes [22]. Sections were blocked in
goat serum (5% (v/v)) in PBS supplemented with triton-
X100 (0.05% (w/v)) for 1 h in a humidified chamber at
room temperature. Sections were incubated with pri-
mary antibodies overnight at 4 °C. Primary antibodies
used were: rat anti-K8, rabbit anti-SMA, rabbit anti-E-
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cadherin, mouse anti-E-cadherin and rabbit anti-cleaved
caspase 3. Alexa Fluor conjugated secondary antibodies
were diluted 1:500. Nuclei were counterstained with
DAPI (1–5 μM).
Optical clearing and measurement of sample size changes
Mammary tissue pieces were processed using 3DISCO,
PACT-RC, PACT-sRIMS, CUBIC or SeeDB-based tissue
clearing protocols, and images were acquired on a dissect-
ing microscope (Leica MZ75) with constant exposure,
gain and magnification. For quantification of sample size
changes, image thresholding was performed using ImageJ
(v1.49p, National Institutes of Health) and the pixel area
was measured [9]. Volume changes were calculated as the
ratio of the pixel area before and after tissue clearing.
Confocal microscopy
Tissues cleared by 3DISCO, PACT-sRIMS, CUBIC and
SeeDB were imaged in their respective RI matching solu-
tions in Ibidi μ-Dishes. PACT-RC-cleared tissues were
mounted using iSpacer chambers in RC-CS Mounting
Medium. Images were acquired using a Leica TCS SP8
inverted confocal microscope with 10×/0.4 or 20×/0.75
HC PL APO objective lenses. Laser power and gain were
adjusted manually to give optimal fluorescence intensity
for each fluorophore with minimal photobleaching. Step
size and line averaging were kept constant for all main
figures (line averaging, 16; step size 1–2), excluding
CUBIC and SeeDB depth cueing examples. Imaging
depths were recorded from the top of the epithelial
structure being imaged (typically 350 μm through the
native fat pad for the CUBIC and SeeDB protocols).
Image reconstructions were generated using Imaris
image management software (v8.0, Bitplane) or ImageJ
(v1.50c, National Institutes of Health) [23, 24]. Depth
coding was performed using the Temporal Colour Code
plugin with the spectrum LUT. De-noising of 3D image
sequences was performed in MATLAB (R2014a, The
Mathworks Inc.) [25].
Two-photon and light sheet fluorescence microscopy (LSFM)
Two-photon imaging was performed on a LaVision
BioTec TriM Scope II with a 25×/1.05 water dipping
lens and an insight DeepSee dual-line laser (tuneable
710–1010 nm and fixed 1040 nm lines), with 810 nm
wavelength used to excite DAPI and HER2-AF647. Tiled
images, having a 20% overlap, were stitched together using
the Grid Collection/Stitching plugin in ImageJ [26].
For LSFM, samples were immunostained and cleared
according to the CUBIC protocol [10]. After clearing,
samples were embedded within an agarose (1% (w/v) in
H2O) tube, prepared by aspirating agarose (37–38 °C)
into a pre-warmed 1-mL syringe in which the syringe
neck had been cut off. Mammary tissue strips were
quickly placed within the agarose tube using forceps and
centred by rolling the syringe between the palms. After
setting, the plunger was removed and the entire syringe
was submerged in CUBIC reagent 2. Samples were im-
aged in reagent 2 or glycerol in H2O (34% (w/w)).
The light sheet system was a home-built modified ver-
sion of the OpenSPIM system [27]. The microscope was
built and operated in the T-SPIM layout, whereby illu-
mination happens from two sides simultaneously by
overlapping two individual sheets to allow a more even
illumination and to reduce artefacts, such as striping.
We used two Olympus 5×/0.15 air lenses to generate the
light sheet. The higher refractive indices, long working
distance (20 mm) and the fact that the lenses were on
threaded mounts allowed us to adjust the point of focus
accordingly. The imaging light path was equipped with a
Nikon 16×/0.8 water dipping lens. We imaged onto an
Andor Neo 5.5 (ANDOR) or a Hamamatsu ORCA-
Flash4 V2 (Hamamatsu) with 6.5 um pixels. For excita-
tion a home-built laser combiner was used, bundling
405 nm, 488 nm, 561 nm and 640 (Coherent Cube 405
and 640, Coherent Sapphire 488 and 561) into a single-
mode fibre. Channels were acquired sequentially and
emission was filtered by suitable band-pass or long-pass
filters (DAPI: 447/60; AF647: 705/72; both AHF Analy-
sentechnik). The sample was mounted in a 4D (xyzθ)
stage (Picard Industries) allowing optimal positioning of
the sample in the light sheet. During imaging the sample
was moved through the light sheet with a step size of
1.5 μm and the light sheet thickness was adjusted to be
ca. 6 μm to warrant an even thickness of the sheet
across the entire sample width. Exposure times were be-
tween 15 and 150 ms.
Results
Optical transparency in the mammary gland
We evaluated four passive whole-organ tissue clearing
protocols for optical clarity and morphology preservation
during two distinct phases of mammary gland develop-
ment, puberty and lactation. The PACT protocol was eval-
uated using two RI matching solutions: the commercially
available aqueous-based solution RapiClear CS® (RI = 1.45)
and a more-economical sorbitol-based solution, sRIMS
(RI = 1.46) [18]. Of the four methods tested, PACT-based
protocols [11] were the most time-intensive and labour-
intensive, taking between 10 and 13 days for completion
(Fig. 1a). In contrast, the simple, immersion-based tissue
clearing protocols CUBIC [10] and SeeDB [9] required
only 5 days (Fig. 1a), and resulted in superior optical clar-
ity in both virgin and lactating tissue (Fig. 1b). CUBIC
clearing provided the highest degree of transparency in
mammary tissue and was also highly effective in decolour-
ising blood vessels (Fig. 1b) [16]. To determine whether
these methods altered the structural integrity of mammary
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Fig. 1 Optical clearing of mammary tissue. a Experimental procedure and timelines for optical clearing of mouse mammary tissue. Black arrows
show the stage at which (optional) immunostaining may be performed. The experimental timeline can be altered depending on the size and
nature of the tissue, and the degree of transparency required. b Transmission images of whole abdominal (fourth) mammary glands (virgin and
lactating) before and after clearing using the passive clarity technique (PACT) with rapiclear (RC) or sorbitol refractive index matching solution
(sRIMS), clear unobstructed brain imaging cocktails (CUBIC) or the see deep brain (SeeDB) clearing protocols. c Volume changes resulting from
optical clearing of virgin and lactating mammary tissue. Values are representative of measurements from three tissue pieces from each clearing
protocol at each developmental time point. See additional file 18 for a high resolution version of these PDFs and http://rdcu.be/lT3Z for
additional high resolution examples of these imaging techniques [38]
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tissue, as has been reported for other clearing protocols
[12, 28], we measured the sample volume of fixed mam-
mary tissue before and after tissue clearing protocols were
applied (Fig. 1c). PACT-RC and CUBIC were associated
with a moderate degree of tissue expansion, which was
more prominent during lactation. A small reduction in
sample volume was observed with SeeDB (Fig. 1c).
We also tested the solvent-based tissue clearing proto-
col 3DISCO (Additional file 2: Figure S2a), a method
previously employed for tissue clearing in the mammary
gland [8]. Using 3DISCO, we observed shrinkage of both
virgin and lactating mammary tissue samples, which was
associated with significant structural deformations to ducts
and lactational alveoli (Additional file 2: Figure S2b-d). Al-
though this protocol was extremely rapid to implement
(Additional file 2: Figure S2a), achieved a high degree of
optical clarity (Additional file 2: Figure S2b) and may be
useful in other organ systems [8], its application to the
mammary gland, which was left brittle and damaged from
the clearing process, is extremely limited. Additionally, the
solvents used in this protocol pose significant laboratory
safety risks and require specialised imaging chambers [8].
For these reasons we did not pursue 3DISCO further for
optical clearing of mammary tissue.
PACT-based tissue clearing and 3D imaging of the
unsectioned mouse mammary gland
We assessed PACT-based clearing approaches for the visu-
alisation of mammary epithelial cells in virgin and lactating
mammary glands in situ. When combined with whole-
mount immunostaining, these protocols required 17
(PACT-RC) to 20 (PACT-sRIMS) days preparation prior to
imaging (Additional file 3: Figure S3a and Fig. 2a) [11].
Samples prepared using the PACT-RC protocol are not
stable in the RI matching solution, and thus require
mounting in a specialised mounting medium (SunJin
Labs). Whilst this approach is conducive to long-term sam-
ple storage, the limited working distances of standard con-
focal microscope objectives makes imaging of PACT-RC-
mounted samples problematic, as samples cannot be re-
orientated against the coverglass for optimal sample illu-
mination (Additional file 3: Figure S3b-c). Consequently,
we chose to pursue PACT-sRIMS for whole-mount immu-
nostaining and 3D imaging in this study. However, we note
that this is purely a hardware issue, and PACT-RC may be
useful with more specialised imaging objectives [18].
PACT-sRIMS permitted imaging of surface structures
(Fig. 2b) at marginally improved depths over uncleared
tissue (Additional file 4: Figure S4). Using PACT-sRIMS
combined with 3D de-noising algorithms (Additional file 5:
Figure S5) [25], we were able to visualise surface epithelial
structures in 3D at high cellular resolution (Fig. 2b, c and
Additional file 6: Figure S6). Figure legends provide a
link to higher resolution files. Lactating tissue was
particularly amenable to 3D imaging, due to the lower
content of adipocytes and the increased surface epithe-
lial mass (Fig. 2c). Using this approach, we were able to
observe K5-expressing and SMA-expressing basal cells
and K8-expressing and E-cadherin-expressing luminal
cells, with confidence.
CUBIC tissue clearing and 3D imaging of the unsectioned
mouse mammary gland
Like PACT-sRIMS, CUBIC clearing allowed visualisation
of the virgin and lactating mammary epithelia at high
cellular resolution (Fig. 3, Additional file 7: Movie 1 and
Additional file 8: Figure S7). Additionally, due to the
high degree of optical transparency achieved by CUBIC
clearing, deeper structures could be readily visualised
and imaged using this method (Fig. 3). Whilst we ob-
served strong immunostaining with K5 and SMA anti-
bodies using the CUBIC method, K8 and E-cadherin
were not readily and uniformly observed in these condi-
tions. This could be due to sub-optimal fixation or a re-
sult of differential protein loss caused by exposure to
high levels of detergent without prior sub-cellular stabil-
isation using a hydrogel monomer. However, using a re-
cent modification to the CUBIC Reagent 1 formulation
(Reagent 1A, see “Methods”), we observed improved im-
munostaining of K8 and E-cadherin (Additional file 9:
Figure S8), suggesting that epitope availability is better
preserved with this new reagent. The stability of various
genetically encoded fluorescent proteins (FPs), including
GFP, YFP and RFP, was also assessed and found to be
adequately preserved through CUBIC processing
(Additional file 10: Figure S9a, b).
We determined that CUBIC-cleared samples were
amenable to rehydration, paraffin embedding and immu-
nohistochemical staining following whole-mount imaging
(Additional file 10: Figure S9c), facilitating the subse-
quent 2D cellular analysis of whole-mount-imaged mam-
mary structures. On account of the high level of optical
clarity achieved using CUBIC-based tissue clearing and
its compatibility with subsequent 2D imaging, we also
evaluated its utility for whole-mount histochemical ana-
lysis (Fig. 4). Currently, carmine is the most prevalent
histochemical stain for assessing mammary gland mor-
phogenesis in whole mount. This pigment stains the
mammary epithelia an intense pink/red colour and relies
on the solvent xylene or methyl salicylate for subsequent
optical transparency [29, 30]. Here, we developed and
optimised an alternative histochemical stain for the
mammary gland, using the cationic dye methyl green
and CUBIC tissue clearing. Using this approach we were
able to achieve delicate green/blue staining of epithelial
structures in the mammary gland of virgin and
lactating mice (Fig. 4a). This new staining approach
offers improved colour palette flexibility for dual-
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Lactating mammary gland
Virgin mammary gland
a
b
30 µmK5 DAPI
Day 0 1 2 3 4 5 6 7 8 9 10 11 12 13
PACT- sRIMS A4P0 PACT hydrogel PACT clearing solution WashFix
Block Primary Antibody Secondary Antibody& DAPI = 20 days
sRIMS
SMA DAPI
K8 DAPI E-CAD DAPI
z = 6 µm
z = 13 µm
z = 8 µm
z = 14 µm
z = 2 µm
z = 11 µm
z = 23 µm
z = 20 µm
z = 29 µm
c
K8 DAPI
K5 DAPI
E-CAD DAPI
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z = 44 µm
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Fig. 2 Passive clarity technique (PACT)-sorbitol refractive index matching solution (sRIMS) clearing and 3D imaging of virgin and lactating mouse
mammary tissue. a PACT-sRIMS tissue clearing and immunostaining protocol and timeline. Three-dimensional confocal imaging of PACT-sRIMS-
cleared virgin (b) and lactating (c) mammary glands immunostained with basal cell markers (K5 and smooth muscle actin (SMA)) and luminal cell
markers (K8 and E-cadherin (E-CAD)). Main image shows the maximum intensity projection of the entire image sequence, with thin optical slices
(1 μm) and their depth (z value) relative to the first image in the image sequence. These images are representative of images from at least two
mice; further examples of PACT-sRIMS-cleared tissue are shown in Additional file 6: Figure S6). DAPI 4′,6-diamidino-2-phenylindole. See additional
file 18 for a high resolution version of these PDFs and http://rdcu.be/lT3Z for additional high resolution examples of these imaging techniques
[38]
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colour staining, for example with the novel magenta
β-glucosidase (SYNbglA) reporter [19] (Fig. 4b). CUBIC
clearing was also semi-compatible with the more trad-
itional whole-mount histochemical stains carmine and
haematoxylin (Additional file 11: Figure S10), although
these were not the focus of this study and staining may be
improved with further optimisation. Importantly, CUBIC
clearing was compatible with whole-mount DAB immu-
nohistochemical analysis (Fig. 4c), which has not previ-
ously been achieved in the mammary gland.
SeeDB tissue clearing for 3D imaging of the unsectioned
mouse mammary gland
Similar to CUBIC clearing, mammary ducts and
alveoli could be imaged at high cellular resolution
and at considerable depths using SeeDB clearing (Fig. 5,
Additional file 12: Movie 2 and Additional file 13:
Figure S11). SeeDB-cleared mammary tissue was highly
compatible with all antibodies (Fig. 5) and endogenous
fluorochromes tested (Additional file 14: Figure S12a, b),
with structural morphology well preserved by this simple
CUBIC Reagent #1Fix Reagent #2
Block Primary Antibody Secondary Antibody& DAPI = 12 days 
Day 0 1 2 3 4 5 6 7 8 9 10 11 12 13
Virgin mammary gland
K5 DAPI
z = 7 µm
z =13 µm
z = 28 µm
30 µm 30 µm
z =10 µm
z = 31 µm
z = 49 µm
SMA DAPI
E-CAD DAPI 30 µm
z = 17 µm
z = 19 µm
z = 22 µm
Lactating mammary gland
30 µm
K5 DAPI 30 µm
z = 6 µm
z = 9 µm
z = 16 µm
z = 19 µm
z = 32 µm
z = 67 µm
SMA DAPI
K8 DAPI
z = 18 µm
z = 24 µm
z = 29 µm
30 µm
30 µm
z = 8 µm
z = 11 µm
z = 18 µm
30 µmE-CAD DAPI
BV
z = 14 µm
z = 18 µm
z = 25 µm
a
b
c
K8 DAPI
117 µm 0 
z 
Depth coding
SMA 
BV
Depth coding
40 µm 0 
z 
BV
SMA 
Fig. 3 Clear unobstructed brain imaging cocktails (CUBIC) clearing and 3D imaging of virgin and lactating mouse mammary tissue. a CUBIC tissue
clearing and immunostaining protocol and timeline. Three-dimensional confocal imaging of CUBIC-cleared virgin (b) and lactating (c) mammary
glands immunostained with basal cell markers (K5 and smooth muscle actin (SMA)) and luminal cell markers (K8 and E-cadherin (E-CAD)). Main image
(green) shows the maximum intensity projection of the entire image sequence, with thin optical slices (1 μm) and their depth (z value) relative to the
first image in the image sequence. Right panel shows depth-coding of SMA-expressing cells; images in an image stack are assigned a colour
based on their relative depth. These images are representative of images from more than three mice; further examples of CUBIC-cleared tissue
are shown in Additional file 8: Figure S7 and a modified (Reagent 1A) CUBIC protocol in Additional file 9: Figure S8). BV blood vessel (SMA-expressing).
DAPI 4′,6-diamidino-2-phenylindole. See additional file 18 for a high resolution version of these PDFs and http://rdcu.be/lT3Z for additional high
resolution examples of these imaging techniques [38]
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fructose-based clearing technique. Additionally, SeeDB-
cleared samples were also highly compatible with rehydra-
tion and additional whole-mount immunostaining or with
paraffin embedding, sectioning and 2D immunostaining
(Additional file 14: Figure S12c). Collectively, these prop-
erties of optical transparency, morphology preservation,
quality of whole-mount immunostaining and suitability
for rehydration and 2D analyses, made SeeDB our pre-
ferred method for 3D fluorescence imaging of the mam-
mary gland.
Three-dimensional imaging of mammary tumours
We also tested the performance of PACT-sRIMS,
CUBIC and SeeDB clearing protocols on mouse mam-
mary tumours derived from the syngeneic TUBO cell
line [17]. All clearing protocols permitted high reso-
lution imaging of HER2-expressing cells in mammary
tumours at enhanced depths (Fig. 6 and Additional file
15: Movie 3). Similar to virgin and lactating tissue, K8
immunostaining was less intense in CUBIC-cleared
mammary tumours (Fig. 6b), but may be improved by
the second generation formulation (Reagent 1A). We ob-
served that HER2, K8 and DAPI fluorescence intensity
was reduced with increasing imaging depth in all proto-
cols (Fig. 6). Whilst this may in part be attributable to a
technical artefact, e.g. sub-optimal fixation or inadequate
antibody penetration, it may also be a reflection of the in-
herent biology and heterogeneity of these tumour samples.
Indeed, 2D immunohistochemical analysis revealed that
the centre of many tumour lobules contained cleaved
caspase-3-positive cells within areas of low E-cadherin
staining (Additional file 16: Figure S13), highlighting
the value of performing 2D analyses and 3D imaging in
parallel when characterising complex and heteroge-
neous specimens.
Finally, we utilised two-photon excitation microscopy
(TPEM) and light sheet fluorescence microscopy (LSFM)
for rapid, large-scale imaging of normal and tumouri-
genic mammary tissue at improved depths and speeds
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Fig. 4 Clear unobstructed brain imaging cocktails (CUBIC) clearing
for whole-mount transmission imaging of the mouse mammary
gland. a Virgin and lactating mammary glands stained with methyl
green and cleared with CUBIC for whole-mount morphometric
analysis. These images are representative of images from more
than three mice. b Methyl green counterstaining, showing the
compatibility of this light green counterstain with magenta-glu
detection of β-glucosidase+ cells; β-glucosidase+ cells are interspersed
with unlabelled cells in this R26[CA]30SYNbglA mouse model. c Compatibility
of CUBIC clearing with smooth muscle actin (SMA)-immunostaining
and horseradish peroxidase-3,3-diaminobenzidine detection.
Immunostaining steps can be performed before CUBIC clearing
(top panel) or after CUBIC clearing (bottom panel). See additional file
18 for a high resolution version of these PDFs and http://rdcu.be/lT3Z
for additional high resolution examples of these imaging techniques
[38]
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(Fig. 7 and Additional file 17: Figure S14). TPEM uses
longer wavelengths, thus allowing deeper penetration,
less scattering of light and reduced out-of-focus photo-
bleaching than laser scanning confocal microscopy [31].
Using this technique, we were able to image approx.
1.2 × 1.2 × 0.1 mm of SeeDB-cleared tumour tissue in
less than 15 minutes per individual channel at high cel-
lular resolution (Fig. 7). Deeper imaging was achievable
(Fig. 7, orthogonal projections); however, as seen with
confocal microscopy, HER2 immunostaining declined
with increasing depth (Fig. 7, optical slices). Furthermore,
using a home-built LSFM [27], with dual side illumination,
we were able to image a volume of 0.8 × 0.8 × 1.5 mm in
normal mammary tissue with CUBIC clearing in less
than 5 min per individual channel (Additional file 17:
Figure S14). These data demonstrate that SeeDB-cleared
and CUBIC-cleared mammary tissue are also compatible
with advanced imaging techniques.
Virgin mammary gland
a
30 µmK5 DAPI
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SeeDB Fix 20-100% fructose SeeDB
Block Primary Antibody Secondary Antibody& DAPI = 12 days
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Fig. 5 See deep brain (SeeDB)-clearing and 3D imaging of virgin and lactating mouse mammary tissue. a SeeDB tissue clearing and immunostaining
protocol and timeline. Three-dimensional confocal imaging of SeeDB-cleared virgin (b) and lactating (c) mammary glands immunostained with basal
cell markers (K5 and smooth muscle actin (SMA)) and luminal cell markers (K8 and E-cadherin (E-CAD)). Main image (green) shows the
maximum intensity projection of the entire image sequence, with thin optical slices (1 μm) and their depth (z value) relative to the first
image in the image sequence. Right panel shows depth-coding of SMA-expressing cells; images in an image stack are assigned a colour
based on their relative depth. These images are representative of images from more than three mice; further examples of SeeDB-cleared
tissue are shown in Additional file 13: Figure S11). BV blood vessel (SMA-expressing). DAPI 4′,6-diamidino-2-phenylindole. See additional file
18 for a high resolution version of these PDFs and http://rdcu.be/lT3Z for additional high resolution examples of these imaging tech-
niques [38]
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Discussion
Recent developments and refinements in whole-organ
tissue clearing and 3D imaging techniques, such as LSFM,
optical projection tomography (OPT) and X-ray tomog-
raphy, have provided unprecedented optical access to in-
tact mammalian tissues [32]. These protocols have been
utilised for a range of biological applications, including
neuronal circuit reconstruction [8–11, 15, 28, 33], charac-
terisation of arterial wall structure [34] and single-cell
lineage tracing in the embryonic heart [35]. In this
technical report, we compared leading tissue clearing pro-
tocols for optical transparency, structural preservation
and 3D fluorescent imaging in the intact mammary gland.
This is the first study to employ tissue clearing protocols
to examine mammary epithelial cells at single-cell reso-
lution within their native stroma.
We first assessed these protocols for their ability to
render opaque mammary tissue transparent. SeeDB and
CUBIC clearing techniques achieved the highest degree
of optical clarity in mammary tissue (Table 1). Due to
PACT-sRIMS cleared tumour
CUBIC cleared tumour
SeeDB cleared tumour
z = 4 µm z = 7 µm z = 10 µm z = 13 µm z = 16 µm z = 19 µm z = 22 µm z = 25 µm z = 28 µm z = 31 µm
DAPI  HER2  K8 30 µm
z = 4 µm z = 7 µm z = 10 µm z = 13 µm z = 16 µm z = 19 µm z = 22 µm z = 25 µm z = 28 µm z = 35 µm
DAPI  HER2  K8 30 µm
a
b
c
DAPI  HER2  K8
z = 4 µm z = 7 µm z = 10 µm z = 13 µm z = 16 µm z = 19 µm z = 22 µm z = 25 µm z = 28 µm z = 34 µm
30 µm
Fig. 6 Three-dimensional confocal imaging of mouse mammary tumours cleared with the passive clarity technique (PACT)-sorbitol refractive
index matching solution (sRIMS), clear unobstructed brain imaging cocktails (CUBIC) and see deep brain (SeeDB) methods. PACT-sRIMS cleared
tumour tissue (a), CUBIC-cleared tumour tissue (b) and SeeDB-cleared tumour tissue (c). Images show maximum intensity projections of
4′,6-diamidino-2-phenylindole (DAPI) nuclear staining and human epidermal growth factor receptor 2 (HER2) and K8 immunostaining, with
thin optical slices (1 μm) and their depth (z value) relative to the first image in the image sequence. These images are representative of
at least two regions acquired. See additional file 18 for a high resolution version of these PDFs and http://rdcu.be/lT3Z for additional high
resolution examples of these imaging techniques [38]
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the exceptional clarity achieved using the CUBIC proto-
col, we also investigated its suitability as an alternative
to xylene delipidation for macroscopic imaging of mouse
mammary gland whole mounts. CUBIC clearing com-
bined with methyl green staining resulted in uniform,
single-colour staining of mammary epithelial ducts and
alveoli, and improved-contrast counterstaining for multi-
colour histochemical analysis. Importantly, CUBIC clear-
ing was also compatible with whole-mount chromogenic
immunostaining using HRP-DAB detection. Additionally,
whole-mount-imaged tissue could be easily recovered
and sectioned for subsequent 2D immunohistochemical
SeeDB cleared mammary tumour imaged on 2-photon microscope
z = 16 µm z = 28 µm z = 40 µm z = 52 µm z = 64 µm z = 76 µm z = 88 µm z = 94 µm
HER2  DAPI 100 µm
xz
yz
xz
yz
Fig. 7 Imaging of see deep brain (SeeDB)-cleared mammary tumours using 2-photon excitation microscopy. Two-photon imaging of SeeDB-
cleared human epidermal growth factor receptor 2 (HER2)-positive mammary tumours immunostained with HER2 (green) and 4′,6-diamidino-2-
phenylindole (DAPI) nuclear staining (blue) and magnified view (inset). Orthagonal views show XZ (purple line and box) and YZ (red line and box)
planes. Thin optical slices (2 μm) and their depth (z value) relative to the first image in the image sequence are also shown. See additional file 18 for a high
resolution version of these PDFs and http://rdcu.be/lT3Z for additional high resolution examples of these imaging techniques [38]
Table 1 A comparison of selected clearing methods in the mammary gland
Method Method overview RI Clearing
capability
Durationa Preservation Whole mount
IHC
Long-term
storage
Rehydration
and sectioning
Reference
structure FP
Uncleared No clearing protocol
applied
− − 1 day Preserved Preserved Compatible No Possiblef −
3DISCO Organic solvent-based 1.56 Strong 2 days Compromised Rapid loss Difficultc No Not possible [8]
PACT-RC Aqueous solution-based
(hydrogel embedding)
1.45 Weak 10 days Preserved,
mild expansion
Preserved Compatible Yes Not possible [11]
PACT-sRIMS Aqueous solution-based
(hydrogel embedding)
1.46 Weak 13 days Preserved Preserved Compatible No Possiblef [11]
CUBIC Aqueous solution-based
(simple immersion)
1.48–9 Strong 5 days Preserved,
mild expansion
Some lossb Semi-
compatibled
No Confirmed [10]
SeeDB Aqueous solution-based
(simple immersion)
1.49 Moderate 5 days Preserved,
mild shrinkage
Preserved Compatible Noe Confirmed [9]
aDuration from the time of tissue harvest (includes fixation time typically 6–16 h for mammary tissue). bAs previously reported [10, 39] and the observed
requirement for slightly higher laser power for confocal imaging. This may be improved by using the second generation protocol (using Reagent 1A). cUsing the
three-dimensional imaging of solvent-cleared organs combined with optimised whole-mount immunolabelling procedures iDISCO/three-dimensional imaging of
solvent-cleared organs (3DISCO) method. The fluorescence signal is rapidly quenched using benzyl alcohol benzyl benzoate (BABB) and a specialised imaging
chamber is required for dibenzyl ether (DBE). dSome antibodies (i.e. E-cadherin, K8 and human epidermal growth factor receptor 2) do not perform as well as in
other clearing protocols. eOptimally imaged within 2 weeks but may be stored for several months. fLikely to be compatible, but not tested in this study. RI refractive
index, FP fluorescent protein, IHC immunohistochemical analysis, PACT-RC passive clarity technique-Rapiclear, sRIMS sorbitol refractive index matching solution, CUBIC
clear unobstructed brain imaging cocktails, SeeDB see deep brain
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analysis. For these reasons, we propose CUBIC clear-
ing as a novel, superior clearing agent for mammary
gland whole mounts.
A major limitation of early tissue-clearing techniques
is pronounced sample volume changes, leading to cellular
deformations [12, 28]. Here, we found that mammary tis-
sue cleared with PACT-RC and CUBIC was associated
with a moderate degree of sample expansion, as previously
observed in brain tissue cleared using these techniques
[10, 11]. Conversely, SeeDB was associated with minor
shrinkage of mammary tissue (Table 1), while PACT-
sRIMS had no effect on sample volume. Importantly,
morphological deformations were not observed by con-
focal microscopy for any of the four main tissue clear-
ing protocols assessed in this study. Thus, these small,
predictable changes in linear sample volume are not
likely to pose a major problem for the majority of stud-
ies in the mammary gland, provided the control/com-
parator mammary gland is also subjected to the same
clearing protocol. Additionally, in contrast to mechan-
ical dissection or enzymatic digestion, most optical tis-
sue clearing protocols preserve both tissue and matrix
architecture, and thus facilitate 3D imaging and analysis
of epithelial-stromal interactions.
Whilst important biological information can be gar-
nered from 3D imaging of near-surface structures in un-
cleared tissue [36, 37], the advantages presented by
tissue clearing for the visualisation of expansive areas of
mammary tissue are considerable, e.g. for comprehensive
clonal analysis in lineage tracing studies [38] or mapping
the cellular circuitry driving mammary gland develop-
ment. Using tissue clearing protocols we were able to
image genetically encoded fluorescent proteins and a
range of immunolabelled lineage markers at vastly im-
proved depths and at high cellular resolution in virgin,
lactating and tumour tissue. Adoption of these protocols
combined with volumetric imaging and published de-
noising algorithms will greatly enhance our understand-
ing of the structural organisation and development of
the normal mammary gland, and how these processes
are subverted in cancer. An evaluation of the perform-
ance of these protocols for diagnostic and experimental
studies using clinical tumour biopsies is an aim for the
future.
Although not evaluated in this study, it is expected
that other antibodies, with appropriate optimisation,
would be compatible with whole-mount immunostain-
ing, tissue clearing and 3D imaging in the mammary
gland. Thus, this technique has widespread applications
in the broader fields of mammary gland biology and
pathology. In particular, appropriate optimisation of the
tissue fixation time is paramount for whole-mount im-
munostaining, which is not compatible with heat-
induced epitope retrieval. Reduced performance of some
antibodies was observed with CUBIC clearing in the
mammary gland. This method relies on high concentra-
tions of detergent (15% triton-X100) for clearing and,
unlike the PACT protocol, does not entail prior hydrogel
embedding to stabilise cellular structures, raising concerns
that this protocol may be associated with some protein
loss (Table 1) [10]. Indeed, this may explain the compro-
mised fluorescence immunostaining of K8, E-cadherin
and HER2 observed with the CUBIC clearing protocol in
our study. To overcome this issue an updated CUBIC
protocol has recently been developed (unpublished, see
“Methods”) aimed at improving issues related to protein
loss [39]. Alternatively, samples could be gel-embedded
according to the CLARITY protocol [15] prior to CUBIC
clearing; however, this has not been rigorously assessed in
this or other [10] studies, and would require further opti-
misation for mammary tissue.
An assessment of the qualities of optical transparency,
structural preservation, imaging depth, immunostaining,
compatibility with downstream analyses, cost and safety
(Table 1), placed SeeDB as our method of choice for tis-
sue clearing and volumetric imaging of mammary tissue
using standard confocal and advanced fluorescence im-
aging techniques. The deep tissue imaging of normal
and pathological mammary tissue will greatly improve
our understanding of this architecturally complex and
heterogeneous organ.
Conclusions
This technical report compared the strengths and limita-
tions of a range of whole-organ tissue clearing protocols
for optical transparency and 3D imaging in the mouse
mammary gland. Notably, the methods examined here are
open source protocols, which utilise reagents that are both
widely available and affordable to most laboratories. Add-
itionally, whilst these protocols are compatible with ad-
vanced imaging techniques, they can also be paired with
standard confocal microscopy and open source analysis
platforms for universal use. We hope that this publication
sheds light on the methods available for optical tissue
clearing of the mouse mammary gland, and encourages
other researchers to perform their mammary tissue im-
aging in 3D, with all architectural information preserved.
Additional files
Additional file 1: Figure S1. No primary antibody controls of CUBIC
cleared tissue (top panel) and SeeDB cleared tissue (bottom panel).
See Additional file 18 for a high resolution version of these PDFs. (PDF 243 mb)
Additional file 2: Figure S2. 3DISCO clearing and 3D imaging of virgin
and lactating mouse mammary tissue. a 3DISCO tissue clearing and
immunostaining protocol and timeline. b Transmission images of 3DISCO
cleared tissue. c Volume changes caused by 3DISCO-based clearing
of virgin and lactating mammary tissue. Values are representative of
measurements from three tissue pieces at each developmental timepoint.
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d 3D confocal imaging of 3DISCO-cleared virgin and lactating mammary
glands immunostained with the basal cellb marker SMA. These images are
representative of images from more than two mice. See Additional file 18
for a high resolution version of these PDFs. (PDF 8 mb)
Additional file 3: Figure S3. PACT-RC clearing and 3D imaging of virgin
and lactating mouse mammary tissue. a PACT-RC tissue clearing and
immunostaining protocol and timeline. b The optimal (i) and PACT-RC (ii)
imaging configuration for confocal microscopy. For optimal illumination,
samples are squeezed between two glass coverslips and are easily flipped
or re-positioned for imaging. In contrast, for PACT-RC-cleared samples,
samples are mounted using an iSpacer chamber and are difficult
to adjust or reposition for optimal illumination, thus the working
distance becomes the limiting factor in image acquisition. To overcome
this, sample thickness must be closely matched to the thickness of the
iSpacer chamber, specialised imaging objectives need to be used or
different RI-matching solutions are needed. c 3D confocal imaging of
PACT-RC-cleared virgin and lactating mammary glands immunostained with
the basal cell marker SMA and stained with the nuclear stain DAPI. These
images are representative of images from at least two mice. See Additional
file 18 for a high resolution version of these PDFs. (PDF 124 mb)
Additional file 4: Figure S4. 3D imaging of uncleared virgin and
lactating mouse mammary tissue. a Immunostaining protocol and
timeline, without a tissue clearing step. 3D confocal imaging of uncleared
virgin (b) and lactating (c) mammary glands immunostained with basal
cell marker SMA and the luminal cell marker E-cadherin. Main image
shows the maximum intensity projection of the entire image sequence,
with thin optical slices (1 μm) and their depth (z value) relative to the first
image in the image sequence. Visible structures were located very close
to the surface of the tissue. See Additional file 18 for a high resolution
version of these PDFs. (PDF 176 mb)
Additional file 5: Figure S5. De-noising of 3D image sequences. DAPI
staining (top panel) and E-cadherin immunostaining (bottom panel) in lactating
mammary tissue before and after a de-noising algorithm was applied to
minimise Poisson-Gaussian noise in the 3D image stacks. De-noising does
not greatly alter the outward appearance of the image sequence, but rather
aids downstream computer-assisted analyses. See Additional file 18 for a
high resolution version of these PDFs. (PDF 4 mb)
Additional file 6: Figure S6. Additional 3D confocal images of PACT-
sRIMS-cleared mammary glands, related to Fig. 2. BV blood vessel (SMA-
expressing). See Additional file 18 for a high resolution version of these
PDFs. (PDF 13 mb)
Additional file 7: Movie 1. Three-dimensional rendering of SMA
immunostaining (red) and DAPI nuclear staining (blue) in CUBIC-cleared
lactating mammary tissue. Movie shows a layer of basket-like basal cells
surrounding each alveolus with single cell resolution. (AVI 20400 kb)
Additional file 8: Figure S7. Additional 3D confocal images of CUBIC-
cleared mammary glands, related to Fig. 3. Arrowhead shows non-specific
intraluminal staining occasionally observed with CUBIC clearing, which
may be improved with more rigorous washing following immersion in
Reagent 1. See Additional file 18 for a high resolution version of these
PDFs. (PDF 23 mb)
Additional file 9: Figure S8. Three-dimensional confocal images of
mammary glands cleared using a modified CUBIC clearing protocol
(Reagent 1A) to minimise protein loss. Images show the maximum intensity
projection of the entire image sequence. Bottom right panel shows
depth-coding of SMA-expressing myoepithelial cells in lactating mam-
mary tissue; images in an image stack are assigned a colour based on their
relative depth. Arrowhead shows non-specific intraluminal staining
occasionally observed with modified CUBIC clearing, which may be improved
with further washing. These images are representative of images from two
mice. BV blood vessel (SMA-expressing). See Additional file 18 for a high reso-
lution version of these PDFs. (PDF 12 mb)
Additional file 10: Figure S9. Compatibility of CUBIC clearing with
genetically encoded FPs and recovery for histological sections. a CUBIC
clearing of tissue from R26-Confetti mice with reporter expression (nuclear
GFP, cytosolic YFP and cytosolic RFP) induced at very low, sporadic levels.
Membranous CFP was not observed with any clearing protocol and may be
technical; however, this FP is also reportedly underrepresented in mammary
tissue from R26-Confetti mice. b Tissue from lactating R26-Tdtomato
mice induced at very high levels. c CUBIC-cleared tissue was rehydrated in
PBS prior to standard processing, paraffin embedding and sectioning.
Immunostaining for E-cadherin (luminal) and SMA (basal) markers
confirm the compatibility of CUBIC clearing with tissue recovery and
immunostaining. See Additional file 18 for a high resolution version
of these PDFs. (PDF 126 mb)
Additional file 11: Figure S10. Compatibility of CUBIC clearing with
carmine and haematoxylin whole-mount staining. Carmine staining (top)
shows light pink, non-uniform staining in virgin and lactating tissue.
Haematoxylin staining (bottom) was an intense blue colour in both ducts
and stroma. See Additional file 18 for a high resolution version of these
PDFs. (PDF 30 mb)
Additional file 12: Movie 2. Three-dimensional rendering of SMA
(green) and K8 (red) immunostaining in SeeDB-cleared virgin mammary
tissue. Movie shows luminal and basal cell layers with single cell resolution.
(AVI 32300 kb)
Additional file 13: Figure S11. Additional 3D confocal images of
SeeDB-cleared mammary glands, related to Fig. 5. See Additional file 18
for a high resolution version of these PDFs. (PDF 10 mb)
Additional file 14: Figure S12. Compatibility of SeeDB clearing with
genetically encoded FPs and recovery for histological sections. a SeeDB
clearing of tissue from virgin R26-Confetti mice with reporter expression
(nuclear GFP, cytosolic YFP and cytosolic RFP) induced at very low,
sporadic levels. Membranous CFP was not observed with any clearing
protocol and may be technical; however, this FP is also reportedly
underrepresented in mammary tissue from R26-Confetti mice. b Tissue from
lactating R26-Tdtomato mice induced at very high levels. c SeeDB-cleared
tissue was rehydrated in PBS prior to standard processing, paraffin
embedding and sectioning. Immunostaining for K8 (luminal) and SMA
(basal) markers confirm the compatibility of SeeDB clearing with tissue
recovery and immunostaining. See Additional file 18 for a high resolution
version of these PDFs. (PDF 154 mb)
Additional file 15: Movie 3. Three-dimensional rendering of HER2 (red)
and K8 (green) immunostaining with DAPI nuclear staining (blue) in
SeeDB-cleared mammary tumours. Movie shows optical slices and the
single cell resolution, allowing visualisation of the 3D structure of the
tumour tissue. (AVI 45300 kb)
Additional file 16: Figure S13. Two dimensional immunohistochemical
analysis of tumour fragments. K8 and HER2 (a) and E-cadherin and cleaved
caspase-3 (CC3) (b) immunostaining on formalin-fixed paraffin embedded
tissue sections from mouse mammary tumours. CC3-positive cells can be
observed close to the tumour boundary and in the centre of the tumour
fragment, and thus, are not simply an artefact of sub-optimal tissue fixation.
Dotted line in left panel shows the tissue boundary. DAPI nuclear staining
(blue). See Additional file 18 for a high resolution version of these PDFs.
(PDF 26 mb)
Additional file 17: Figure S14. LSFM imaging in the mammary gland.
SMA immunostaining and CUBIC clearing of mammary tissue from (a)
early gestation (total depth 800 μm) and (b) virgin (total depth 500 μm)
mammary tissue. BV blood vessel (SMA-expressing). See Additional file 18
for a high resolution version of these PDFs. (PDF 9 mb)
Additional file 18: All figures in high resolution. (ZIP 127 MB)
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